Gloperba is a drug owned by Scilex Pharmaceuticals Inc. It is protected by 4 US drug patents filed from 2019 to 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 20, 2037. Details of Gloperba's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10226423 | Colchicine drug-to-drug interactions |
Dec, 2037
(13 years from now) | Active |
| US10383821 | Colchicine drug-to-drug interactions |
Nov, 2036
(12 years from now) | Active |
| US9907751 | Composition and method of use of colchicine oral liquid |
Nov, 2036
(12 years from now) | Active |
| US10383820 | Colchicine drug-to-drug interactions |
Nov, 2036
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Gloperba's patents.
Latest Legal Activities on Gloperba's Patents
Given below is the list of recent legal activities going on the following patents of Gloperba.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 20 Feb, 2023 | US10383820 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 20 Feb, 2023 | US10383821 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Sep, 2022 | US10226423 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 07 Sep, 2021 | US9907751 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Aug, 2019 | US10383821 |
| Recordation of Patent Grant Mailed Critical | 20 Aug, 2019 | US10383821 |
| Recordation of Patent Grant Mailed Critical | 20 Aug, 2019 | US10383820 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Aug, 2019 | US10383820 |
| Email Notification Critical | 01 Aug, 2019 | US10383820 |
| Email Notification Critical | 01 Aug, 2019 | US10383821 |
US patents provide insights into the exclusivity only within the United States, but Gloperba is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Gloperba's family patents as well as insights into ongoing legal events on those patents.
Gloperba's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Gloperba's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 20, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Gloperba Generic API suppliers:
Colchicine is the generic name for the brand Gloperba. 12 different companies have already filed for the generic of Gloperba, with Zydus Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Gloperba's generic
How can I launch a generic of Gloperba before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Gloperba's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Gloperba's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Gloperba -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.6 mg/5 mL | 02 Apr, 2020 | 1 | 20 Dec, 2037 | Non-Forfeiture |
Alternative Brands for Gloperba
Gloperba which is used for preventing gout flares in adults., has several other brand drugs using the same active ingredient (Colchicine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Colchicine, Gloperba's active ingredient. Check the complete list of approved generic manufacturers for Gloperba
About Gloperba
Gloperba is a drug owned by Scilex Pharmaceuticals Inc. It is used for preventing gout flares in adults. Gloperba uses Colchicine as an active ingredient. Gloperba was launched by Scilex Pharms in 2019.
Approval Date:
Gloperba was approved by FDA for market use on 30 January, 2019.
Active Ingredient:
Gloperba uses Colchicine as the active ingredient. Check out other Drugs and Companies using Colchicine ingredient
Treatment:
Gloperba is used for preventing gout flares in adults.
Dosage:
Gloperba is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.6MG/5ML | SOLUTION | Prescription | ORAL |